Biotechnology Companies in India
- 3rd biggest biotech industry in the Asia-Pacific region.
- 2nd highest number of USFDA–approved plants.
- USD 3.7 Billion to be spent on biotechnology from 2012-17.
- No. 1 producer of Hepatitis B vaccine recombinant.
- USD 4.3 Billion bio-economy by the end of 2013.
- USD 100 Billion industry by 2025.
REASONS TO INVEST
- India is amongst the top 12 biotech destinations in the world and ranks third in the Asia-Pacific region.
- India has the second-highest number of USFDA–approved plants, after the USA.
- India adopted the product patent regime in 2005.
- Increasing government expenditure will augment the growth of the sector — the government aims to spend USD 3.7 Billion on biotechnology between 2012-17.
- India is the largest producer of recombinant Hepatitis B vaccine.
- India has the potential to become a major producer of transgenic rice and several genetically modified (GM) or engineered vegetables.
- The Indian biotech industry will grow at an average growth rate of around 30% a year and reach USD 100 Billion by 2025.
- The Indian bio-economy grew to USD 4.3 Billion at the end of 2013, up from USD 530 Million in 2003.
- The Indian biotech industry grew by 15.1% in 2012–13, increasing the market’s revenues from USD 3.31 Billion in 2011-12 to USD 3.81 Billion in 2012–13.
- The market size of the sector is expected to rise up to USD 11.6 Billion by 2017 due to a range of factors such as growing demand for healthcare services, intensive R&D activities and strong government initiatives.
- The Indian biotechnology sector is divided into five major segments — bio-pharma, bio-services, bio-agri, bio-industrial and bio-informatics.
- The bio-pharmaceutical sector accounts for the largest share of the biotech industry with a share of 64% in total revenues in 2013, followed by bio-services (18%), bio-agri (14%), bio-industrial (3%) and bio-informatics (1%).
- Revenue from bio-pharma exports reached USD 2.2 Billion in 2013, accounting for 51% of total revenues of the biotech industry.
- The sector has seen high growth with a CAGR in excess of 20% and the key drivers for growth in the biotech sector are increasing investments, outsourcing activities, exports and the government’s focus on the sector.
- A strong pool of scientists and engineers.
- Cost-effective manufacturing capabilities.
- The setting up of national research laboratories, centres of academic excellence in biosciences, several medical colleges, educational and training institutes offering degrees and diplomas in biotechnology, bio-informatics and biological sciences.
- For global companies looking to economise, outsourcing to lower cost economies results in a cost arbitrage of more than 50%.
- Fast-developing clinical capabilities with the country becoming a popular destination for clinical trials, contract research and manufacturing activities.
- Foreign Direct Investment (FDI) up to 100% is permitted through the automatic route for greenfield and through the government route for brownfield, for pharmaceuticals.
Dr. Mitra, Genova Biotech, Hyderabad, India
India vs Monsanto - seeds of discord
Indian Governement Files Biopiracy Lawsuit Against Monsanto
India: Farmers protest against genetically modified ...
Symposium: Platform Companies in Biotechnology
Pharmaceutical Companies in India